<DOC>
	<DOCNO>NCT02394028</DOCNO>
	<brief_summary>This multicenter , Phase III , double-blind , placebo-controlled study evaluate safety efficacy etrolizumab induction maintenance treatment moderate severely active Crohn 's disease ( CD ) patient anti-tumor necrosis factor ( TNF ) naive ( TNF-naive ) patient refractory intolerant tumor necrosis factor inhibitor .</brief_summary>
	<brief_title>A Study Safety Efficacy Etrolizumab Patients With Moderately Severely Active Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>1880 year age ( inclusive ) Moderately severely active Crohn 's disease determine Crohn 's Disease Activity Index ( CDAI ) , patient report outcome endoscopically define disease activity ileum and/or colon Intolerance , loss response failure respond corticosteroid ( CS ) , immunosuppressant ( IS ) , TNF inhibitor within previous 5 year Use effective contraception define protocol A history , current condition affect digestive tract , ulcerative colitis , indeterminant colitis , fistulizing disease , abdominal perianal abscess , adenomatous colonic polyp excise , colonic mucosal dysplasia , short bowel syndrome Planned surgery CD Ileostomy colostomy Has receive nonpermitted inflammatory bowel disease ( IBD ) therapy ( include natalizumab , vedolizumab , efilizumab , state protocol ) Chronic hepatitis B C infection , HIV , active latent tuberculosis ( patient prior history BCG vaccination must pass protocoldefined screen criterion )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>